Organovo Holdings, Inc. (ONVO)
- Previous Close
0.9881 - Open
0.9881 - Bid 0.8428 x 100
- Ask 1.1700 x 100
- Day's Range
0.9801 - 1.0256 - 52 Week Range
0.8900 - 2.0500 - Volume
139,329 - Avg. Volume
1,023,953 - Market Cap (intraday)
10.078M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1600 - Earnings Date Jul 11, 2024 - Jul 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.55
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
www.organovo.comRecent News: ONVO
Performance Overview: ONVO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONVO
Valuation Measures
Market Cap
9.96M
Enterprise Value
6.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
36.00
Price/Book (mrq)
1.61
Enterprise Value/Revenue
25.47
Enterprise Value/EBITDA
-0.32
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.77%
Return on Equity (ttm)
-134.07%
Revenue (ttm)
242k
Net Income Avi to Common (ttm)
-19.09M
Diluted EPS (ttm)
-2.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.29M
Total Debt/Equity (mrq)
24.28%
Levered Free Cash Flow (ttm)
-10.26M